Beijing News on November 2, according to the official website of the State Food and drug administration, the application for listing and registration of Shanghai Green Valley Pharmaceutical Co., Ltd. ganlute sodium capsule (trade name nine phase one) was approved, which is mainly used for mild to moderate Alzheimers disease and improving patients cognitive function. The drug is a low molecular acid oligosaccharide obtained from the extract of marine brown algae. It is an innovative drug independently researched and developed in China with independent intellectual property rights, and has obtained the major special support of national major new drug creation technology.
Nine phase one is a research team led by researcher Geng Meiyu of Shanghai Institute of pharmaceutical research, Chinese Academy of Sciences. It has been persisting in 22 years, continuously striving to develop successful original new drugs in Ocean University of China, Shanghai Institute of pharmaceutical research, Chinese Academy of Sciences and Shanghai Green Valley Pharmaceutical Co., Ltd. It is also the first new Alzheimers disease treatment drug targeting brain gut axis in the world.
The listing of nine phase one in mainland China through the priority review and approval process is the first time in the world, filling the gap of no new drug listing in this field for 17 years. Because the pathogenesis of Alzheimers disease is very complex, the course of disease is long, and it is difficult to cure, the drug will provide patients with new drug options.
Shanghai Green Valley Pharmaceutical Co., Ltd. said that the company has been well prepared for production and sales, and the drugs will be put on the market within the year. At the same time, green valley will launch nine phase one Post Market Research and real world research, and is actively promoting the international multi center clinical research project, hoping to benefit the global patients as soon as possible.
Shanghai Green Valley Pharmaceutical Co., Ltd. was founded in 1997. It is an innovation driven Chinese pharmaceutical enterprise. It is committed to providing innovative diagnosis and treatment programs for patients with chronic and complex diseases such as neuropsychiatric system disease, cardiovascular disease, tumor and so on. The technology and experience of sugar drug development are its core capabilities. The company has established world-class GMP production bases and corresponding CMC systems in Qingpu, Shanghai and Benxi, Liaoning. Its main product, salvianolic acid salt, ranks among the top 10 single product sales in China for many years.
Source: new Beijing News Author: Zhang Zhaohui editor in charge: Hua Chengyu